Status:
NOT_YET_RECRUITING
Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid
Lead Sponsor:
University Hospital, Rouen
Conditions:
Bullous Pemphigoid
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to validate a global and simple score : IGA (Investigator Global Assessment) score for the evaluation of the extent and severity of the disease in patients with bullous pemphig...
Eligibility Criteria
Inclusion
- Consecutive adult patients aged ≥ 18 years
- Newly diagnosed or relapsing BP
- Clinical features suggestive of classic BP AND suggestive histological features AND deposition of IgG and/ or C3 deposits on the dermal epiderma junction, AND detection of circulating anti-epidermal antibodies labelling the epidermal side of salt-split skin
- Patient having read and understood the information letter and not opposed to participation
- Must be willing and able to adhere to all specified requirements, including but not limited to adherence to the follow-up visits
Exclusion
- Predominant or exclusive mucosal involvement leading to suspect the diagnosis of mucous membrane pemphigoid
- Pemphigoid gestationis
- Linear IgA dermatosis (predominant or exclusive IgA deposits on the DEJ)
- Skin lesions suggesting the diagnosis of epidermolysis bullosa acquisita (skin fragility, atrophy, milia)
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 30 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05366127
Start Date
July 1 2022
End Date
July 30 2026
Last Update
May 9 2022
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Bordeaux University Hospital
Bordeaux, France
2
Dijon University Hospital
Dijon, France
3
Lille University Hospital
Lille, France
4
Lyon University Hospital
Lyon, France